GBP0.07
0.69% today
London, Nov 26, 12:28 pm CET
ISIN
GB00BYWL4Y04
Symbol
RENX

Renalytix AI plc Stock price

GBP0.07
-0.01 9.38% 1M
-0.11 60.81% 6M
-0.08 53.23% YTD
-0.15 67.78% 1Y
-6.93 98.96% 3Y
-2.69 97.37% 5Y
-1.13 93.96% 10Y
London, Closing price Mon, Nov 25 2024
-0.01 6.45%
ISIN
GB00BYWL4Y04
Symbol
RENX

Key metrics

Market capitalization GBP13.77m
Enterprise Value GBP19.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.34
P/S ratio (TTM) P/S ratio 7.40
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -22.16%
Revenue (TTM) Revenue GBP1.86m
EBIT (operating result TTM) EBIT GBP-19.08m
Free Cash Flow (TTM) Free Cash Flow GBP-19.36m
Cash position GBP680.00k
EPS (TTM) EPS GBP-0.20
P/E forward negative
P/S forward 4.22
EV/Sales forward 5.12
Short interest 58.00%
Show more

Is Renalytix AI plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Renalytix AI plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Renalytix AI plc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Renalytix AI plc:

Buy
100%

Financial data from Renalytix AI plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.86 1.86
22% 22%
100%
- Direct Costs 1.62 1.62
21% 21%
87%
0.24 0.24
31% 31%
13%
- Selling and Administrative Expenses 13 13
38% 38%
709%
- Research and Development Expense 5.90 5.90
46% 46%
317%
-19 -19
41% 41%
-1,013%
- Depreciation and Amortization 0.24 0.24
41% 41%
13%
EBIT (Operating Income) EBIT -19 -19
41% 41%
-1,026%
Net Profit -22 -22
38% 38%
-1,193%

In millions GBP.

Don't miss a Thing! We will send you all news about Renalytix AI plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.

Head office United Kingdom
CEO James McCullough
Founded 2018
Website renalytix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today